ArticleCureus2025
Evaluating the Safety of Gastrointestinal Contrast Agents in Pediatric Patients: A Retrospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastrointestinal (GI) contrast imaging is commonly performed in pediatric patients to diagnose and treat various GI conditions. However, a widely held clinical belief suggests that contrast agents may have deleterious side effects on the intestinal wall, particularly in premature infants or those with pre-existing intestinal inflammation. This presumed risk is primarily supported by anecdotal reports and older animal studies.
objectiveThis study aimed to investigate the potential association between GI contrast agent exposure and the development of necrotizing enterocolitis (NEC) within a 30-day period in infants. MATERIALS AND
methodsA retrospective study was conducted at a single tertiary care institution with a level IV neonatal intensive care unit. All 245 infants who underwent any form of GI contrast-enhanced radiological study were included. The primary outcome was the development of NEC within 30 days following exposure to a contrast agent.
resultsA total of 245 patients were included, of whom 15 (6.1%) had a documented history of NEC occurring more than two weeks prior to undergoing contrast imaging. Only one term newborn suspected of NEC progressed to intestinal perforation following contrast agent exposure.
conclusionOur findings suggest that GI contrast agent exposure is generally safe in infants and does not increase the risk of NEC development within 30 days, including premature newborns. However, it may be safer to avoid hyperosmolar contrast agents in patients with active NEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.